|
November
2006
|
|
http://www.alrt.com
|
|
SYMBOL/EXCHANGE
RECENT
PRICE
52
WEEK RANGE
SHARES
OUT.
SHARES
FLOAT
|
|
ALRT
/ OTCBB
$0.10
$.045
- $.22
76.1
MM
35.3
MM
|
|
|
|
|
|
|
|
|
Corporate
Summary
ALR
Technologies Inc. (OTCBB: ALRT) is a pioneer in the emerging market for
the home
health management and disease management industry. While medical researchers
and
pharmaceutical companies have been effective in developing treatments to
manage
many diseases and health issues, poor medication compliance at home, mainly
forgetting when and which medication to take, has rendered the treatments
less
effective. The growing problem of patient non-adherence to medical treatments
contributes to more than $140 billion dollars annually in excess health
care
costs. Health
care costs in the US currently account for 15% of the gross domestic product
and
is expected to reach 25% by 2020.
ALRT
has
developed a technology-based "clinically proven" system, the Constant
Health Companion™
to
address the problem of patient non-adherence. The Constant
Health Companion
will
serve as a medication reminder for the patients at home, monitor the patients'
compliance to prescribed medical treatments and, if necessary, facilitate
timely
intervention by their health care providers.
At
the
present time, current US health management practices fall far short as
patients
are left largely on their own after they are discharged from the hospital,
leave
the medical clinic or after the case manager leaves their homes. The
Constant
Health Companion
will
enable remote and continued oversight of the patients by their health care
providers. The system will provide the necessary information for health
care
providers to improve treatment adherence by their patients resulting in
more
favorable health outcomes and containment of health care costs. ALRT is
focused
on becoming the leader and driver of growth for the emerging health management
compliance market.
With
the
ALRT health management products and systems, health care providers can
now
remind patients what to do at the appropriate times, determine patients'
compliance and intervene when necessary. Improving compliance and intervening
on
a real time basis will result in better health outcome and reduce the overall
cost of healthcare. Accordingly, use of the Constant
Health Companion
will
realize significant return on investment. Furthermore, the Constant
Health Companion
system
will provide valuable information for financial decision-making. Insurance
providers can monitor plan members' compliance and adjust the pricing of
their
coverage based on adherence by the members to prescribed health management
programs.
In
the
course of developing the Constant
Health Companion
over the
past five years, the company has also developed other spin-off compliance
reminder products such as the ALRT PC 200, and other specialized products
targeting specific health care needs.
ALRT
has
recently completed in-market pilots and trials with patients suffering
from
chronic conditions such as congestive heart failure, diabetes, organ transplant,
HIV/AIDS as well as with assisted living organizations and Medicaid patients.
Companies that participated in the pilots reported significant return on
investment and improved health outcome results. These companies are also
committing to use the ALRT system in their business operations. ALRT is
starting
its first full manufacturing run for product delivery in January
2007.
RECENT
HEADLINES
Nov
8, 2006
- ALR
Tech’s Constant Hlth Companion to Fill a Serious Gap in Current Health Mgmt
Practices Making Healthcare Cost Reduction a Reality
Oct
30, 2006
- Apple
Patch Community Receives Invitation to Present the ALRT500 Compliance System
at
the 2006 Institute for Behavioral Health Informatics
Oct
23, 2006
- Heart
Transplant Patient Reports Significant Results With Medication and Treatment
Compliance Using the ALRT500 Home Health Management System
Oct
18, 2006
-
Medicaid Asthma Patients to Utilize the ALRT500 Health Mgmt System
Aug
24, 2006
-
Medicaid Group Grants PageMinder Approval for Use of ALRT500 Health Mgmt
Product
With Chronic Patients
In
an abstract based on a Columbia University Clinical Trial, presented to
the 12th
World AIDS Conference in Geneva, ALRT’s earlier version of the PC100™ was shown
to improve the frequency of patients taking 100% of their medication doses
by
97% and to improve the frequency of patients taking 100% of their medication
doses at the correct time of day by 168%, which in turn, improved the overall
health outcome of the study participants.
|
Corporate
Profile - ALR Technologies, Inc.
|
Page
2
|
Investment
Highlights
Documented
Emerging Marketplace
$140
billion in healthcare costs are reported due to noncompliance of medical
treatments and ALRT has the answers to solve this problem. Disease Management,
Health Insurance Payers and Case Management companies are now looking to
find a
solution for this problem. Limiting factors such as cost, ease of use,
and
portability have been overcome by ALRT with their system.
Industry
Leader
ALRT
has
established itself as a pioneer in the disease management compliance
marketplace, with a complete variety of medication compliance reminders
and
monitors. The ALRT systems can be monitored by a healthcare provider, homecare
companies or family members and offer the essentials such of affordability
and
ease of use which are necessary to develop this market.
Significant
Cost Over Competition
The
marketplace clearly has tremendous potential and there are only a handful
of
companies trying to service it. ALRT’s products and services cost to the
consumer is at least 31% lower than the next least expensive system, with
the
company still generating healthy margins.
Patent-pending
Technology
ALRT
is
the only company with a Nebulizer Monitoring System; this monitoring System
is
patent-pending and allows the company to dominate a marketplace of 16 million
people suffering from Chronic Obstructive Pulmonary Disease (COPD) as well
as
applicability to the millions of people who suffer from acute asthma. Patents
received apply to the single button, ease of use features that are part
of each
of the ALRT products and systems.
Constant
Health Companion™ and Monitoring Enters Commercialization
Phase
ALRT
has
completed its internal pilot testing on the Constant
Health Companion
system
and has now finalized in-market pilot programs with several commercial
disease
management and homecare service companies. The first full-scale manufacturing
run is scheduled for delivery in January 2007.
History
Founded
in 1998, and incorporated under the laws of the State of Nevada, the company
was
established to address a growing need in the disease management industry;
that
need being patients’ adherence with medications and other disease management
activities. Noncompliance is a world-wide problem of striking magnitude.
Having
focused their efforts on the development of the Constant
Health Companion
and the
Home Health System (a disease management monitoring system) the company
also
successfully made available the ALRT Med Reminder in 2003 soon followed
by the
ALRT PC100 as well as monthly reminders for veterinary pharmaceuticals
for the
prevention of heartworm disease in dogs and cats. The ALRT PC200, a second
generation of the PC100 was designed in early 2005 in response to specific
needs
addressed by companies providing mail order medications and disease management
services. The company has now completed development of the Constant
Health Companion
and
monitoring system and full-scale manufacturing is to begin in the fall
of 2006.
While
developing the ALRT compliance system, the company has also successfully
secured
patent protection and patent-pending status for a series of
products.
|
Patent
|
Description
|
|
Provisional
Patent App. Serial No. 60/652,237
|
Medical
Reminder Device Suited for Use with Nebulizer
|
|
Nonprovisional
Patent App. Serial No. 10/462,096
|
Portable
Programmable Medical Alert Device
|
|
Claims
Benefit of Provisional Patent App. Serial No. 60/388,264
|
Portable
Programmable Medical Alert Device
|
|
Provisional
Patent App.Serial No. 60/388,264
|
Portable
Programmable Medical Alert Device
|
|
US
Patent D446,740
|
Ornamental
Design of a Medication Alert Device in the Shape of a
Heart
|
|
US
Patent D446,739
|
Ornamental
Design of a Medication Alert Device in the Shape of a Dog
Bone
|
|
US
Design Patent D447,074
|
Ornamental
Design of a Medication Alert Device in the Shape of a Stylized
Paw
|
|
Corporate
Profile - ALR Technologies, Inc.
|
Page
3
|
Management
and Directors
Sidney
S. Chan
Mr.
Chan,
Chairman and Chief Executive Officer of ALR Technologies Inc. has made
a
significant contribution to the Company since first becoming involved in
August
1997. He has assisted the company’s financing and its evolution into a public
company. Most importantly, he has also directed the company’s product
development. Mr. Chan has extensive relationships with Hong Kong area based
technology and electronic manufacturers----helping assure the availability
of
low cost manufacturing and materials procurement. Mr. Chan is an engineer
and
obtained his Bachelor of Engineering (Mining) degree with distinction in
Mineral
Economics from McGill University in 1973.
Stan
Cruitt
Stan
Cruitt joined ALR Technologies as President in 2000, bringing with him
more than
20 years of experience in the pharmaceutical industry. He became President
at a
key point in the company’s history, when ALRT was evaluating its products and
considering innovative uses for medication reminders throughout the healthcare
community.
Mr.
Cruitt has extensive experience in the pharmaceutical industry, where he
has
held numerous positions ranging from serving as a marketing research analyst
with Merck to top marketing and management positions with Ciba and Novartis.
In
1996, Newsweek
and
Advertising
Age recognized
him as one of the top marketers in the United States. Mr. Cruitt’s experience at
building brands, markets and business is a needed fit for ALRT. Mr. Cruitt
received his undergraduate degree from Southern Illinois University and
received
academic honors during graduate study.
Jaroslav
V. Tichy, Ph D
Since
December, 2000, Dr. Tichy has been Vice President of Technology for the
company.
From 1984 through 2000, Dr. Tichy was a Systems Design Specialist with
Weir-Jones Engineering Consultants Ltd. Dr. Tichy has conducted research
and
lectured in a wide range of areas including asynchronous switching theory,
signal theory and pattern recognition. In addition, he has been involved
in a
number of development projects including analog, digital and mixed circuit
design, digital signal processing and microprocessor and microcontroller
based
systems. Dr. Tichy received both his Ph.D and MSc. Degrees in Computer
Technology from the Technical University in Brno Czech Republic.
Advisory
Board
Michael
Baumgarner, PhD
Chief
Executive and President of Burke, Inc. - Dr. Baumgardner has been the President
of Burke, Inc., since 1994 and CEO since 2004. Headquartered in Cincinnati,
OH,
Burke, Inc., is one of the premier international marketing research and
consulting firms, with offices and affiliates in 40 countries.
Arnold
da Silva
Vice
President and General Manager, Schenker of Canada Limited - Schenker of
Canada
Limited is one of the leading international providers of integrated logistics
and freight-forwarding services at over 1,000 locations around the
world.
William
Lorentz, M D
Dr.
Lorentz is the Associate Chief of Professional Services at North Carolina
Baptist Hospital and serves as Professor of Pediatrics of the Wake Forest
University Medical School. Dr. Lorentz is also Medical Director, MedCost,
Inc.,
a leading PPO in North Carolina.
Betsy
Pearce
Vice
President and Chief Operating Officer of Niblock Financial Systems, Inc.
Niblock
is one of the largest providers of banking equipment and financial systems
software in the United States, with headquarters located in
Winston-
Salem,
NC.
Ronald
H. Small
Vice
President, Quality Outcomes and Chief Pharmacy Officer for Wake Forest
University Baptist Medical Center. Ron is also Adjunct Professor of Pharmacy
Practice with the University of North Carolina and Campbell schools of
Pharmacy
and Lecturer in Hospital Administration at Wake Forest University. Some
of the
many organizations he is a member of include: APhA (Fellow), ASHP (Fellow),
ASPEN and ACCP. Ron has contributed to the professional body of knowledge
on
topics such as TQM, Pharmacoeconomics, and Pharmaceutical Care, including
the
concept of Continuity of Care. Ron currently serves on the Advisory Board
of
Premier Purchasing Partners, an organization representing over 1900 hospitals.
|
Corporate
Profile - ALR Technologies, Inc.
|
Page
4
|
Market
Potential
It
is
estimated that there are 110 million people in the US alone taking medications
or treatments for chronic conditions. According to a 1997 Health Economics
analysis by the University of Arizona’s School of Pharmacy, noncompliance
of medication contributed nearly $77 billion in excess annual medical care
cost.
This number is thought to have exceeded $140 billion in
2004.
In 2005,
a New England Journal of Medicine study confirmed that 33% to 69% of
medication-related hospital admissions in the US are due to poor medication
adherence, with a resultant cost of approximately $100 billion a year.
The rate
of non-compliance for a number of chronic diseases has been documented
as
follows:
|
Condition
|
Non-compliance
|
|
Epilepsy
|
30-50%
|
|
Diabetes
|
40-50%
|
|
Hypertension
|
40%
|
|
Asthma
|
20%
|
|
Anticoagulants
|
30%
|
The
next
significant growth area in healthcare and the one area to help contain/reduce
costs is health management compliance and monitoring. Currently, the marketplace
for compliance monitoring is directed to heart disease and a select few
of the
other most severe ailments. The systems that are currently available are
very
narrow in their focus due to the highly targeted population, and high cost
of
the systems. Compliance and monitoring of health management treatments,
medications and other activities have significant untapped market size
potential, as awareness and the availability of affordable and user friendly
effective systems are established.
In
a
market size of this magnitude, just a small percentage of market penetration
can
translate to significant market potential for ALRT products. The respiratory
market potential alone includes more than 16 million people with COPD,
4 million
who use a nebulizer to deliver medication to their lungs 3 to 4 times every
day.
Compliance with this is essential for maintaining quality of life and preventing
rapid deterioration. If ALRT were to establish their nebulizer monitoring
system
(the company has the only nebulizer monitoring system in the world) with
JUST
1% of the 4 million users of nebulizers the first year revenue would be
$19
million with gross profit of approximately $14 million.
With
several other disease conditions having equal or greater potential, this
level
of revenue and profit could be achieved in multiple population groups,
such as
mental illness, and diabetes and heart disease.
HEALTH
INSURANCE INDUSTRY
Healthcare
costs in the US account for 15% of the gross domestic product and is expected
to
reach 25% by 2020. The insurance industry readily admits that enhanced
compliance will lead to lower costs of healthcare. Currently there is no
available system that can assist insurers to assess the degree of compliance
to
prescribed medical treatments by their plan members. The ALRT monitoring
systems
will provide an affordable means for the insurance provider/payers to improve
targeted plan members compliance, and monitor their compliance by incorporating
the Constant
Health Companion
and
monitoring system into their program, insurance payors (corporations with
self
insured plans, Medicaid and Medicare) will be able to reduce costs of providing
care by monitoring plan members with disease conditions where noncompliance
will
significantly increase healthcare costs.
Additionally,
insurance payors will be able to base co-pay or plan premiums on the level
of
compliance or provide discounts to those who are compliant. The health
insurance
payer has the most to benefit in ROI through the incorporation of compliance
enhancement and monitoring/intervention products and systems. Depending
on the
disease condition, the annual savings per targeted patient could range
from
several hundred dollars to several thousand dollars.
ASSISTED
LIVING ORGANIZATIONS
Companies
providing assisted care services are often penalized by state regulatory
boards
when medication errors or other noncompliance are apparent. The ALRT system
will
keep the caregiver compliant and thus reduce errors thereby reducing costly
penalties from state funded plans. The ROI is significant and the benefits
achieved are realized by the patients with improved health outcomes, by
the
payers with better health and reduction of cost of care, and by the assisted
living company with caregiver’s job made easier and reduction in costly
penalties. One
medium sized national assisted living organization alone could utilize
nearly
10,000 ALRT systems which would generate nearly $5 million in 12 month
revenue
for ALRT with 75% gross profit margin.
|
Corporate
Profile - ALR Technologies, Inc.
|
Page
5
|
Market
Potential Continued
COPD
Nearly
16
million people in the US suffer from Chronic Obstructive Pulmonary Disease
or
COPD; of these more than 4 million people take medication through nebulizers
(a
device which delivers medication with compressed air that breaks the medication
particle size down and more effectively delivers the medication to the
lungs).
The COPD and respiratory care patients consist primarily of patients with
lung
failure issues related to bronchitis and emphysema. Many of these patients
have
to use nebulizer medications three to four times a day for the rest of
their
life. Health insurance providers are spending billions of dollars for case
managers to look after their patients, and once the case manager has left
a
patient’s home, the patient once again is left on their own to administer their
medication, many of times which they are non-compliant. ALRT
is positioned to dominate the nebulizer market, with the only Nebulizer
Monitoring System to be available, supported by pending patent protection.
In
addition to the COPD patients use of nebulizers, many of the millions of
people
who suffer from severe asthma also require the use of the nebulizer and
many of
the home care providers who service the COPD population also provide services
to
those with severe asthma.
ORGAN
TRANSPLANT
There
have been nearly 300,000 organ transplants over the past 10 years and more
than
30,000 new transplants annually. Adherence to treatments in organ transplant
patients can rapidly affect the life of the patient. The number one reason
a
child loses a kidney transplant is because parents forget to give the
medication. ALRT can assist organ transplant patients in maintaining a
rigid
medication schedule. The cost of losing a transplanted organ is significant
in
that the health of the recipient is at risk and another transplant becomes
necessary. The monetary cost can be several hundred thousand dollars per
case.
The ROI for the family and the health insurance provider is obvious and
the
benefit of a transplant center offering the monitoring system is the added
value
of care along with differentiation from other centers. A
pilot with an organ transplant patient commenced in February of 2006 and
the
ongoing results have been nearly 100% compliance
and
astatic users have said it has helped make their life much easier. A marketing
program to all organ transplant programs in the US will begin in late fall
of
2006.
MENTAL
HEALTH
There
are
currently 44 million mental health patients being treated with medication
in the
US alone. The high-price of medical non-compliance of mental health patients
not
only affects the patients and their immediate caregivers, mental health
patients
suffering from bi-polar and schizophrenia and other panic disorders can
also
generate significant cost to society. ALRT has already generated attention
with
experts in the mental health industry and commercial pilots are expected
to
begin in first quarter of 2007.
HIV
/ AIDS
There
are
approximately 1 million patients in the US receiving treatment for HIV
and AIDS.
Treatment programs often involve complex regimens and adherence is essential
to
maintaining the health of the patient by keeping the disease in check.
The ALRT
compliance reminder products have already displayed their ability to enhance
compliance via the Columbia University clinical trial and more recently,
ALRT
products have been selected for a major project for HIV patients in Kenya
that
is funded by the NIH (National Institute of Health), and sponsored by the
University of Nairobi and the University of Washington. As the awareness
of the
value of the ALRT compliance reminder products become known in this population,
which exceeds 40 million worldwide, marketing to the many organizations
that
provide assistance to this population will be launched.
OTHER
MARKETS
In
addition to the company’s target markets, we believe that there will be
significant need for the ALRT compliance monitoring system in other disease
categories which include but are not limited to 16
million patients with diabetes, 20 million patients with Asthma, and millions
of
patients with heart disease, congestive heart failure, coronary artery
disease,
diabetes, Parkinson’s disease and Alzheimer’s disease.
|
Corporate
Profile - ALR Technologies, Inc.
|
Page
6
|
Products
and Services
All
of
ALRT’s products are tailored towards disease management and compliance
monitoring which helps to generate better health outcome to the patient
and
lower the overall cost of care to the provider. The products are affordable,
portable, and easy to use. The patient/user does not require a PC to allow
monitoring, only a phone jack; making it easy for elderly patients.
Our
product line consists of Medication Reminder Devices, Compliance Monitoring
Systems, Monitoring and Intervention Systems, and a Diagnostic Test Monitoring
System. In addition, diagnostic data monitoring capability has already
been
programmed in the ALRT system and will be added to the commercial offering
in
the future.
Constant
Health Companion™ Compliance Reminder and Monitoring System
The
Constant
Health Companion™
(aka
ALRT500) Compliance Reminder and Monitoring System has been the primary
development focus of the company, as a result of qualitative research conducted
in 2000 with leaders in the healthcare industry. The Constant
Health Companion
is
designed to manage the medical and health compliance needs for anyone suffering
from a chronic condition including HIV/AIDS, diabetes, cystic fibrosis,
CHF
(Congestive Heart Failure) COPD, organ transplantation, and mental
health.
The
Constant
Health Companion,
not
only reminds a person to take the necessary health management medications
or
other actions at the appropriate time(s) of day but it also displays on
a LCD
screen the exact actions to conduct, allows users to access critical data
such
as medical clinic names and phone numbers and any precautions from use
of
medications. The Constant
Health Companion
makes it
possible for insurance providers, case managers and/or family members of
elderly
patients to monitor a patient’s proper compliance of medication and compliance
of other disease management activities. The system also has proven beneficial
as
a reminder to caregivers in assisted living organizations - to assist the
caregiver in completing the many tasks as scheduled.
The
value
of monitoring are many; including more timely intervention which can prevent
deteriorating conditions, ER visits, etc. and prompt case managers to initiate
additional behavior education and patient training on the necessity of
adherence
to their health management treatment regimen. A study conducted by the
Missouri
Medicaid Program showed a $3,400 annual reduction in cost of care for each
diabetic patient using a disease management compliance reminder
ALRT
Nebulizer Compliance Monitoring
ALRT
is
the only company that offers a nebulizer monitoring system. This system
will be
commercially available along with the Constant Health Companion. The
Constant
Health Companion
connects
to a custom port at the nebulizer compressor switch, and can be adapted
to all
types of nebulizers at minimal costs. This system monitors the use of the
nebulizer by:
| |
·
|
Recording
time of day used
|
| |
·
|
Recording
length of time used
|
| |
·
|
Alerting
healthcare providers or caretakers when person is noncompliant
|
| |
·
|
Allowing
for timely intervention when a patient is
noncompliant
|
| |
·
|
Recording
nonscheduled nebulizer events which can assist a caregiver in
better
understanding a patient’s behavior in using the
nebulizer
|
|
Corporate
Profile - ALR Technologies, Inc.
|
Page
7
|
Products
and Services Continued
ALRT
PC200
The
ALRT
PC200
is our
second generation medication reminder system and is currently available
on the
market. The PC200
can be
customized for each patient’s need and can be programmed by their healthcare
provider at the medical clinic or by their disease management provider
and
mailed directly to the patient. The PC200
is a
stand-alone medical reminder without the attached monitoring system. This
reminder system is light weight, easily transportable, and gives healthcare
providers a simple tool to help keep their patients on schedule with the
medication.
Specialized
Products
In
addition to our primary products, the company has also developed a successful
line of specialized products targeting specific healthcare needs, including
the
Contact
Lens Reminder,
the
48
Hour Reminder,
the
Weekly
Reminder,
and the
Monthly
Reminder.
These
products are designed primarily for pharmaceutical manufacturers and retail
distributors. Many medications are now offered for weekly administration and
monthly administered medications are also now available for osteoporosis.
Patients who are switched from daily to weekly or monthly are thought to
have
even higher prevalence of noncompliance.
A
specialized product designed specifically for the veterinary pharmaceutical
market, the ALRT
Pet Reminder,
is a
medication reminder product for pet treatments and medications. By reminding
the
pet owner to administer a medication on schedule, the ALRT Pet Reminder
can help
optimize a drug's therapeutic benefit to the pet. Nearly 40 million dogs
and
cats in the US alone receive heartworm preventatives. The ALRT pet reminder
has
been shown to improve pet owner compliance with heartworm preventives by
25%.
Missed doses of heartworm preventatives can result in the pet contracting
this
potentially deadly disease.
Competition
Although
there are now a few companies offering disease management home monitoring
systems, they are focused on specific population targets and most systems
lack
portability. Also,
the ALRT system cost to the market is significantly lower than other
competitors, with the company still generating very healthy
margins.
Competitor’s hardware costs range from $100 to $3,000.
The
ALRT
system is being offered at no cost for the hardware with a 12 month contract
for
compliance service. The compliance service fee is $40 per month with continuous
monitoring, reminders and messaging. The ALRT system, in the future will
also
provide similar features offered by a few competitors such as linkage to
diagnostic or medical equipment to record and transmit diagnostic data
to
medical professionals and caregivers.
The
ALRT
system provides many features that these competitors do not, such as compliance
reminders, compliance with medications, compliance with treatments, compliance
with use of nebulizers, and reminders to use diagnostic tools. Other competitors
offer medication management systems that are narrowly targeted to people
taking
many different medications and who are at risk of overdosing or taking
the
incorrect medication. ALRT also offers a medication management system that
reminds patients when to take their medication, the type of medication,
and the
dosage amount at a significantly lower cost.
A
comparison chart can be found on page 8.
|
Corporate
Profile - ALR Technologies, Inc.
|
Page
8
|
Competition
Continued
Below
is
a comparison of the product features of current medication compliance monitoring
systems on the market.
|
Company
|
Compliance
Reminders
|
Monitoring
Compliance of Meds and Treatments
|
Monitoring
Compliance of Diagnostic Testing
|
Monitoring
Diagnostic Data Recorded
|
Medication
Management System
|
Auto
Medication Delivery System
|
Monitoring
Use of Nebulizer
|
Lowest
Cost
|
Full
Range of Reminder Scheduling
|
|
ALR
Technologies
|
X
|
X
|
X
|
in
2007
|
X
|
|
X
|
X
|
X
|
|
Cybernet
|
X
|
|
X
|
X
|
|
|
|
|
|
|
Health
Buddy
|
X
|
|
X
|
X
|
|
X
|
|
|
|
|
HomMed
|
X
|
|
X
|
X
|
|
|
|
|
|
|
Informedix
|
X
|
X
|
X
|
X
|
X
|
X
|
|
|
|
|
Nex
Dose
|
X
|
X
|
|
|
X
|
|
|
|
|
Growth
Strategy
The
company’s goals are to make the ALRT compliance monitoring systems a ‘standard
operating procedure’ (SOP) by health insurance payers and their contracted
disease and case management companies.
Progress
and results to date reveal significant recognition of need within the health
insurance payer industry, the assisted living organizations and the special
needs markets such as COPD, organ transplantation, diabetes and heart disease.
With the aging population and increasing number of elderly due to the aging
of
the “boomer population” the need for the ALRT system will continue to achieve
healthy growth as the boomers age. The increasing availability of disease
treatment and prevention remedies creates an ever increasing need to assist
the
patient with the actions they require to complete on repetitive basis.
The
ALRT system provides ongoing support and continuing oversight of the patient
where current health management practices fall short.
ALR
Technologies is currently raising additional capital, which will help the
company to speed up entry into the marketplace with targeted market promotions.
Besides being used for sales and marketing, proceeds will be applied to
manufacturing and inventory build-up, research and development and debt
relief.
ALR
Technologies, Inc.
Important
disclaimer
This
corporate profile is presented as a brief company overview for the information
for investors, analysts and other parties with an interest in the Company.
ALR
Technologies, Inc.’s management hopes that this corporate profile encourage
analysts and investors to investigate more about the Company through its
Securities and Exchange Commission (SEC) filings, press releases and other
public materials. This corporate profile does not constitute an offer to
sell or
a solicitation of an offer to buy any securities of the Company. This corporate
profile contains forward-looking statements, including, in particular,
statements about ALR Technologies plans, strategies and prospects. These
statements are based on the Company’s current assumptions, expectations and
projections about future events, which are subject to a wide range of business
risks. The Company encourages investors to review the information regarding
the
risks inherent to ALR Technologies and its industry, as described in its
Annual
Report on Form 10-K, as amended by Form 10-K/A, for the year ended December
31,
2004, copies of which are available free of charge over the Internet at
the
SEC’s website at http://www.sec.gov and at the Company’s website at
www.alrt.com. This corporate profile does not purport to be all-inclusive
or to
contain all of the information that a reader may desire as to the structure
or
the affairs of the Company. Although the Company believes that the assumptions
reflected in these forward-looking statements are reasonable, the Company
can
give no assurance that these assumptions will prove to be correct or that
financial or market forecasts, savings or other benefits anticipated in
the
forward-looking statements will be achieved. Forward-looking statements
are not
guarantees of future performance and actual results may differ materially
from
those projected. The information contained in this corporate profile is
only
current as of October 1, 2006 and the Company undertakes no obligation
to update
this corporate profile. In the interest of full disclosure, we call the
reader’s
attention to the fact that the Mercom Capital Group, llc is an investor
relations firm hired by the Company for a monthly fee of $7,500, and has
earned
2,000,000 stock options of the ALRT stock. The stock options can be exercised
at
a price of $.25 per share. Mercom Capital Group, llc is not a registered
financial advisor. Penny stocks are highly speculative and are unsuitable
for
all but very aggressive investors. Always consult a registered financial
advisor
before making any decisions.
|
Corporate
Headquarters
ALR
Technologies, Inc.
tel:
1.336.722.2254
e-mail:
alrt@mercomcapital.com
web
site: www.alrt.com
|
|
Investor
Relations Contact:
Mercom
Capital Group, llc
tel:
1.512.828.6645
e-mail:
alrt@mercomcapital.com
web
site: www.mercomcapital.com
|
